Take a fresh look at your lifestyle.

CureVac sinks in the bag after achieving only 47% efficacy in a trial of its vaccine



Brutal hit on the stock market for the German pharmaceutical company CureVac, which plummets 39% on Wall Street and 44% on the Frankfurt Stock Exchange, after communicating this Wednesday that its candidate for the CVnCoV vaccine against the coronavirus achieved 47% efficiency in interim analysis, which means that it fails to meet the specified statistical criteria for its success.

The CureVac vaccine, which was considered a key candidate in the international race for coronavirus drug approval, been in a phase 2b / 3 clinical trial for a while, which is a key stage for its approval.

In fact, until the beginning of this month, the company has been waiting for the European Medicines Agency (EMA) to approve its use based on data from the clinical trial.

For his part, CureVac CEO Franz-Werner Haas said the company was expecting stronger results in the interim analysis and that the trial, which is currently in progress, it will continue until the final analysis is obtained. "The final effectiveness could still change," he encouraged.

. (tagsToTranslate) CureVac (t) sinks (t) bag (t) after (t) achieve (t) only (t) efficacy (t) trial (t) vaccine (t) Category: All (t) Category: Company News (t) Category: Others (t) Category: Pulsos (t) mostread_empresas


Leave A Reply

Your email address will not be published.